Elanco Animal Health Incorporated, headquartered in Greenfield, Indiana, United States, is a global leader in animal health, offering products and services to enhance the health, performance, and well-being of animals. Founded in 1954 as a division of Eli Lilly & Co., Elanco became an independent public company in 2018 and has since grown into one of the largest standalone animal health companies in the world.
Core Business and Product Offerings
Elanco’s diverse portfolio serves both the companion animal and livestock sectors with a wide array of treatments and solutions:
-
Pet Health Products
- Seresto: Flea and tick collar offering 8 months of protection
- Advantage II: Topical flea treatment for cats and dogs
- K9 Advantix II: Protection against fleas, ticks, and mosquitoes
- Credelio: Monthly oral flea and tick treatment
- Interceptor Plus: Heartworm, roundworm, and tapeworm control
- Trifexis: Combination flea, heartworm, and intestinal parasite treatment
- Zenrelia: Anti-inflammatory treatment for chronic conditions
-
Farm Animal Health Products
- Rumensin: Enhances feed efficiency and prevents coccidiosis in cattle
- Baytril: Broad-spectrum antibiotic for livestock
- Cydectin: Parasite control for cattle and sheep
- Increxxa: Injectable antibiotic for respiratory diseases in cattle
- Bovaer: Reduces methane emissions from dairy cattle
- Component: Hormonal implants for growth promotion in cattle
These products are used globally to improve animal health, food security, and sustainability in agriculture.
Specialisation and Core USP
Elanco is distinguished by its research-driven approach, regulatory expertise, and commitment to sustainability. Core strengths include:
- Strategic integration of Bayer Animal Health (2020), expanding global reach and product diversity
- First-to-market methane-reducing feed additive (Bovaer) for dairy cattle
- Focused investment in innovation through Elanco R&D Innovation Campus
- Global scale with localized product strategies for emerging and developed markets
Financials and Scale of Operations
As a publicly traded company on the NYSE (ticker: ELAN), Elanco reports consistent financial growth:
- FY 2023 Revenue: $4.4 billion
- Market Presence: Over 90 countries
- Employees: More than 9,000 worldwide
- Manufacturing Sites: 19 globally, including sites in the U.S., Europe, and Latin America
Elanco dedicates nearly 8% of revenue annually to R&D, underlining its innovation-driven strategy.
International Shipments
Trade data and corporate reports confirm:
- Top Export Markets: Brazil, Germany, China, Australia, India
- High-Demand Products: Companion animal flea and tick treatments, cattle feed efficiency products
- Global Regulatory Footprint: Products registered in over 100 countries
Elanco maintains robust logistics and regulatory teams to manage complex global supply chains.
Target Markets
Elanco’s customers include:
- Veterinarians and veterinary clinics
- Livestock producers and integrators
- Pet owners and pet retailers
- Government and non-profit partners in animal health initiatives
Elanco also collaborates with public and private entities on zoonotic disease control and food system sustainability.
Capabilities
- Advanced biologics and small molecule production
- Digital platforms supporting veterinary diagnostics and telemedicine
- Veterinary technical support and educational outreach programs
- Climate-focused R&D, including tools to reduce environmental footprint in animal agriculture
The company’s One Health strategy integrates human, animal, and environmental health considerations in product development.
Certifications and Compliance
Elanco maintains global regulatory compliance and high-quality manufacturing practices:
- FDA, EMA, and USDA approvals for veterinary pharmaceuticals
- GMP-certified manufacturing facilities worldwide
- ISO 9001 and ISO 14001 certified operations for quality and environmental management
These credentials ensure product efficacy, safety, and traceability.
Customer Testimonials
End-user satisfaction and product efficacy are widely documented:
- “Seresto remains our best-selling product for long-term flea control. Clients love its reliability.” — Veterinary Clinic, USA
- “Rumensin has significantly improved our feed-to-gain ratio and reduced health issues in our herd.” — Feedlot Manager, Brazil
Major Achievements
- Acquisition of Bayer Animal Health for $7.6 billion in 2020, making Elanco the second-largest animal health company globally
- Development of Bovaer, the world’s first feed additive proven to cut methane emissions in dairy cows
- Recognized in the Dow Jones Sustainability Index for leadership in animal health innovation
- Awarded Fast Company’s “Most Innovative Company” title in health sector (2022)
Elanco Animal Health continues to lead the way in creating solutions that advance animal welfare, support sustainable food systems, and promote public health through innovation and science-backed solutions.
